Year: 2024

Pharming Group to participate in November investor conference

Written by Customer Service on November 5, 2024. Posted in Public Companies.

Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of November:Jefferies London Healthcare Conference 2024, London, U.K., November 19-21Sijmen de Vries, Chief Executive Officer, will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Jefferies representative. About Pharming Group N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq:...

Atos signs binding agreement to sell Worldgrid to ALTEN for an enterprise value of €270 million

Written by Customer Service on November 5, 2024. Posted in Mergers And Acquisitions.

Press Release Atos signs binding agreement to sell Worldgrid to ALTEN for an enterprise value of €270 million Paris, France – November 5, 2024 – Following its press release dated June 11, 2024, Atos, a global leader in digital transformation, high-performance computing and information technology infrastructure, today announces that it has signed a Share & Asset Purchase Agreement with ALTEN SA (“ALTEN”) for the sale of its Worldgrid business unit for an enterprise value of €270 million. Worldgrid provides consulting and engineering services to energy and utility companies. The business currently employs close to 1,100 employees and, in 2023, it generated revenue of circa €170 million from a diverse and longstanding client base. ALTEN is a well-recognized IT and engineering player with expertise and product offerings in the energy...

Coloplast A/S – Announcement no. 05/2024 – Coloplast expands Executive Leadership Team

Written by Customer Service on November 5, 2024. Posted in Public Companies.

Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of our 2025 strategy. In this strategic period, Coloplast has made significant investments to expand the reach of the company and build four growth platforms, Chronic Care, Voice & Respiratory Care, Advanced Wound Care and Interventional Urology, which must drive value creation in the years to come. We are expanding the ELT to reflect this,” says Kristian Villumsen, Coloplast CEO. One Chronic Care organisationIn the new ELT, the Chronic Care business, which includes the Innovation unit and the commercial organisation, will be gathered under one senior leader: Nicolai Buhl, Executive Vice President, Chronic Care. “In our current strategic...

argenx to Participate at Upcoming Investor Conferences

Written by Customer Service on November 5, 2024. Posted in Public Companies.

November 5, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:Guggenheim Inaugural Healthcare Innovation Conference. Fireside chat on Tuesday, November 12, 2024 at 2:30 p.m. ET in Boston, MA.Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 20 and Thursday November 21, 2024 in London, UK.A live webcast of the Guggenheim fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days...

WISe.ART Announces “MINDREAMER” Exhibition from Ylan Anoufa

Written by Customer Service on November 5, 2024. Posted in Public Companies.

WISe.ART Announces “MINDREAMER” Exhibition from Ylan Anoufa Exhibition accompanied by Ylan Anoufa art sales benefiting foundation for childhood education Geneva, Switzerland – November 5, 2024: WISeKey International Holding Ltd. (“WISeKey” or the “Company”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) innovations, today announced that its subsidiary WISe.ART is proud to support Ylan Anoufa’s upcoming “MINDREAMER’ exhibition and new collection of twin phygital art packages. The exhibition is set to premiere November 13 at Geneva-based gallery Gallery Re Source. Proceeds from sale of the packages will benefit Ylan’s foundation for childhood education. “MINDREAMER” at Gallery Re Source Internationally renowned French contemporary artist Ylan Anoufa captivates...

Start of the construction of the first stage of Arena Garden Towers residential project (Riga, Latvia)

Written by Customer Service on November 5, 2024. Posted in Public Companies.

Apartment block viewApartment block view visualisationCourtyard viewCourtyard view visualisationSIA Merks Mājas, part of AS Merko Ehitus group, has launched the first stage of Arena Garden Towers residential project in Skanste district in Riga. One 13-storey building with 84 apartments at Arēna St. 1 will be completed in the summer of 2026. Arena Garden Towers (skanste.merksmajas.lv) residential building will have energy class A rating. The size of the standard apartments ranges between 53 and 105 square meters and the price per square meter ranges from 2,659 to 3,250 euros. The development project comprises in total of four residential buildings with around 400 apartments and two commercial units. Arena Garden Towers is located in Skanste district which is known as a modern center of Riga. This is the first residential...

SYENSQO – Third Quarter 2024 Results

Written by Customer Service on November 5, 2024. Posted in Public Companies.

SYENSQO THIRD QUARTER 2024 RESULTS Brussels, Belgium – November 05, 2024 – 07:00 CET RETURN TO VOLUME GROWTH WITH 5% YEAR-ON-YEAR INCREASE AND ROBUST MARGINS IN A CHALLENGING MARKET ENVIRONMENT Underlying (€ million) Q3 2024 Q3 2023 Q2 2024 YoY change YoY organic QoQ change 9M 2024 9M 2023 YoY change YoY organicNet sales 1,633 1,629 1,708 0.2% 1.6% -4.4% 4,965 ...

CoinShares Announces Q3 2024 Results

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

5th November 2024 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European investment company specialising in digital assets, has today published its results for the quarter ending 30th September 2024. Jean-Marie Mognetti, Chief Executive Officer of CoinShares said: “In Q3 2024, we concentrated on executing our strategy and preparing for a promising Q4 and the upcoming year. A key achievement was the change in our accounting policy for digital assets. We now record movements on digital assets at fair value through profit and loss, enhancing the transparency of our financial statements. This change enables a wide range of investors to have a better understanding of CoinShares’ financial performance and health. We have concurrently implemented bitcoin...

Coloplast A/S – Annual Report 2023/24 & Remuneration Report 2023/24

Written by Customer Service on November 5, 2024. Posted in Public Companies.

Coloplast A/S – Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million.Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 11%, Advanced Wound Care 10% (Advanced Wound Dressings 8%) and Interventional Urology 5%. Kerecis contributed 4%-points to reported growth, with an underlying growth of around 35%, in line with expectations. EBIT1 was DKK 7,286 million, a 6% increase from last year. The EBIT margin1,2 was 27% against 28% last year, mostly impacted by the dilution from Kerecis of around 100 basis points, as expected, and negative impact from currencies. ROIC after tax before special items was 15% against 17% last year, negatively impacted by the acquisition of Kerecis....

Coloplast A/S – Full-Year Financial Results 2023/24

Written by Customer Service on November 5, 2024. Posted in Public Companies.

2023/24 Announcement of full-year financial results 1 October 2023 – 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months).Organic growth rates by business area: Ostomy Care 6%, Continence Care 10%, Voice and Respiratory Care 12%, Advanced Wound Care 10% (Advanced Wound Dressings 4%) and Interventional Urology 7%. Growth in Chronic Care was broad-based and includes improvement in growth in the US which benefited from the resolution of the supply disruptions. Ostomy Care growth was held back by Emerging markets, reflecting a higher baseline in Q4 last year. Continence Care growth was broad-based across segments and includes significant...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals